The Globe and Mail reports in its Saturday, Nov. 15, edition that ATB Capital Markets analyst Chris Murray has reaffirmed his "outperform" ranking for Atkinsrealis Group. The Globe's David Leeder writes in the Eye On Equities column that Mr. Murray gave his share target a $3 boost to $121. Analysts on average target the shares at $116.12. Mr. Murray says in a note: "The adjusted EBITDA beat was driven by better-than-expected growth in nuclear, offsetting limited organic growth in engineering services. Full-year guidance was revised to account for performance in ES and nuclear to date in 2025 and implies expectations for a reversal in ES-based organic growth beginning in Q4/25. The backlog reached $21-billion, reinforcing healthy demand conditions and providing the foundation for stronger levels of organic growth in 2026, with management remaining constructive on the outlook for its regions/sectors entering 2026. We would remain buyers of Atkinsrealis given the recent pullback in the shares, with demand for nuclear, backlog growth in ES, M&A and balance sheet flexibility all supportive of the outlook heading into 2026." The Globe reported on Nov. 4 that Canaccord rated Atkinsrealis "buy." It was then worth $97.88.